- Home
- EQR vs ROIV Comparison
EQR vs ROIV Comparison
Compare EQR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQR | ROIV |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3B | 20.7B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EQR | ROIV |
|---|---|---|
| Price | $62.81 | $29.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $69.35 | $28.94 |
| AVG Volume (30 Days) | 2.2M | ★ 4.1M |
| Earning Date | 04-28-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.64% | N/A |
| EPS Growth | ★ 8.09 | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $2,701,075,000.00 | $29,053,000.00 |
| Revenue This Year | $4.07 | N/A |
| Revenue Next Year | $3.14 | $744.61 |
| P/E Ratio | $20.58 | ★ N/A |
| Revenue Growth | ★ 4.76 | N/A |
| 52 Week Low | $57.57 | $10.01 |
| 52 Week High | $72.40 | $30.33 |
Technical Indicators
Market Signals| Indicator | EQR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 63.00 | 64.70 |
| Support Level | $61.90 | $20.46 |
| Resistance Level | $64.20 | $30.33 |
| Average True Range (ATR) | 1.05 | 0.90 |
| MACD | 0.36 | 0.17 |
| Stochastic Oscillator | 96.74 | 92.32 |
Price Performance
Historical ComparisonAbout EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.